A source of information and resource for small investors - "Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label Merck. Show all posts
Showing posts with label Merck. Show all posts

Saturday, June 22, 2024

Agenus Inc. (formerly known as Agenus Therapeutics) is not claiming to be close to a cure for any form of cancer, but they are making significant strides in developing innovative cancer therapies.

 

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi




Agenus is focused on immuno-oncology, to leverage the immune system to fight cancer. 

Here are some of their notable developments:

  1. Checkpoint Inhibitors: Agenus has been working on various checkpoint inhibitors, which are drugs designed to block proteins that prevent the immune system from attacking cancer cells. Their pipeline includes anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, which are well-known targets in cancer immunotherapy.

  2. Next-Generation Bispecific Antibodies: These are engineered to bind to two different targets simultaneously. This approach can help direct immune cells more effectively to cancer cells.

  3. Cell Therapy: Agenus has been exploring the potential of cell therapy, particularly with their iNKT cell therapy platform. This involves using engineered invariant natural killer T cells to target and destroy cancer cells.

  4. Neoantigen Vaccines: Agenus has been developing personalized cancer vaccines that target neoantigens, which are unique mutations found in an individual's tumor. This personalized approach aims to enhance the immune response against cancer cells.

  5. Combinations and Partnerships: Agenus is also known for combining their therapies with those of other companies, either through collaborations or licensing agreements. These combinations are designed to improve the efficacy of existing treatments and explore new therapeutic avenues.

While these advancements are promising and show potential in treating various forms of cancer, it is important to note that a "cure" for cancer is a complex and multifaceted goal. Cancer is a group of diseases with diverse characteristics, and what might work for one type of cancer or patient may not work for another. Thus, the focus remains on developing effective treatments that can extend survival and improve quality of life for cancer patients.

The progress of Agenus in clinical trials and their collaborations with other companies in the biotech and pharmaceutical industry are steps towards potentially transformative cancer treatments. However, claiming a cure would be premature without further extensive clinical validation and regulatory approval.

Agenus Inc. has formed several strategic partnerships with various pharmaceutical and biotechnology companies to advance its immuno-oncology pipeline. These collaborations aim to leverage the strengths of each partner to develop and commercialize innovative cancer therapies. Here are some notable partnerships:

  1. Gilead Sciences:

    • In December 2018, Agenus entered into a partnership with Gilead Sciences. Gilead received worldwide exclusive rights to Agenus' bispecific antibody program and access to its proprietary cancer immunotherapy platform. The deal included an upfront payment, potential milestone payments, and royalties on future sales.
  2. Incyte Corporation:

    • Agenus has multiple collaborations with Incyte Corporation. The first, established in 2015, involved the development and commercialization of checkpoint inhibitors targeting GITR, OX40, and TIM-3. In 2017, they expanded their partnership to include an exclusive global license for an undisclosed novel target and additional collaborative work on undisclosed novel antibody candidates.
  3. Merck & Co. (MSD):

    • Agenus has collaborated with Merck to evaluate the combination of Agenus' QS-21 Stimulon adjuvant with Merck's vaccines. QS-21 Stimulon is an adjuvant used to enhance the body's immune response to vaccines.
  4. Betta Pharmaceuticals:

    • In 2020, Agenus partnered with Betta Pharmaceuticals to develop and commercialize balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody) in Greater China. This partnership aims to expand the clinical and commercial reach of these immuno-oncology assets.
  5. UroGen Pharma:

    • Agenus and UroGen Pharma collaborated to explore the potential use of Agenus' anti-CTLA-4 antibody zalifrelimab in combination with UroGen's RTGel™ delivery platform for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
  6. Boehringer Ingelheim:

    • In 2021, Agenus entered into a partnership with Boehringer Ingelheim to research and develop novel bispecific antibodies in the field of immuno-oncology. The collaboration includes upfront payments, milestones, and royalties on future sales.

These partnerships highlight Agenus' strategy to collaborate with leading companies to enhance the development and potential commercialization of its immuno-oncology therapies.

Through these collaborations, Agenus aims to accelerate the development of innovative treatments and expand its global reach in the oncology market.

Promising cancer treatments in it's pipeline coupled with a healthy financial book and future royalties positions Xencor for success!

The Human body is highly "Adaptive" in fighting disease, and these two companies are developing technology right now to help that system fight Cancer!


Thursday, June 13, 2024

Consolidation in the BioTech realm is a given going forward. Ginkgo Bioworks technology looks attractive to larger companies in the space!



Ginkgo Bioworks, a prominent player in the synthetic biotech market, could be a potential target for acquisition or merger, especially if consolidation in the industry intensifies. Ginkgo's strengths lie in its platform for designing custom microbes for a variety of applications across industries like pharmaceuticals, agriculture, and industrial biotechnology. Here are some potential acquirers or merger partners for Ginkgo Bioworks:

Potential Acquirers or Merger Partners

  1. Pharmaceutical Giants

    • Pfizer: With its strong focus on biotechnology and recent ventures into mRNA technology, acquiring a company like Ginkgo could bolster its synthetic biology capabilities.
    • Merck & Co.: Known for its research-driven approach and interest in biotech innovation, Merck could leverage Ginkgo’s capabilities to enhance its drug discovery and development processes.
  2. Agricultural Biotech Firms

    • Bayer CropScience: Already a leader in agricultural biotech, Bayer could integrate Ginkgo’s microbial engineering to enhance crop protection and productivity solutions.
    • Corteva Agriscience: As a major player in agriculture, Corteva could benefit from Ginkgo's innovations in developing sustainable and efficient agricultural products.
  3. Industrial Biotech Companies

    • DuPont (now part of DuPont de Nemours, Inc.): With a history of investments in biotechnology, DuPont could utilize Ginkgo’s technology for industrial applications such as bio-based chemicals and materials.
    • DSM (Dutch State Mines): Specializing in health, nutrition, and materials, DSM could integrate Ginkgo’s synthetic biology platforms to drive innovation in bio-based products.
  4. Technology and Innovation-Driven Companies

    • Thermo Fisher Scientific: Known for providing analytical and laboratory services, Thermo Fisher could use Ginkgo’s synthetic biology platform to expand its offerings in bioproduction and bioprocessing.
    • Illumina: As a leader in genetic sequencing, Illumina might find value in Ginkgo’s expertise in genetic engineering to complement its sequencing technologies and expand into synthetic biology applications.

Strategic Rationale for Acquisition

  • Technological Synergy: Larger firms with existing biotech capabilities can leverage Ginkgo’s advanced technology to enhance their product pipelines, improve efficiency, and reduce costs.
  • Market Expansion: Acquiring Ginkgo could help companies expand into new markets, such as bio-based chemicals, sustainable agriculture, and novel pharmaceuticals.
  • Innovation Boost: Ginkgo’s innovative platform and expertise could accelerate research and development efforts, enabling faster time-to-market for new products.
  • Competitive Edge: In a rapidly evolving biotech landscape, having Ginkgo’s cutting-edge capabilities could provide a significant competitive advantage.

Overall, as the synthetic biotech market evolves, consolidation is likely, and Ginkgo Bioworks, with its robust platform and diverse applications, stands out as an attractive target for acquisition or merger by larger companies seeking to strengthen their position in this dynamic field.


Partners closest to Ginkgo

Several companies listed have existing partnerships or collaborations with Ginkgo Bioworks, particularly in the biotechnology, pharmaceuticals, and agriculture sectors. Here are some close partners:

  1. Bayer: Ginkgo Bioworks has a significant partnership with Bayer in the agricultural sector. They formed a joint venture called Joyn Bio to focus on developing microbial solutions for sustainable agriculture, particularly in nitrogen fixation to reduce the need for chemical fertilizers.

  2. Roche: While Roche itself may not have a direct partnership, Ginkgo has been involved in projects related to the pharmaceutical sector that could align with Roche's interests.

  3. Illumina: Ginkgo Bioworks and Illumina have collaborated on projects involving next-generation sequencing and bioinformatics, which are crucial for synthetic biology applications.

  4. ExxonMobil: Ginkgo Bioworks and ExxonMobil have been working together on developing biofuels. This partnership aims to use synthetic biology to produce sustainable and cost-effective biofuels.

These partnerships demonstrate Ginkgo Bioworks' strategic collaborations across different sectors, enhancing their technological capabilities and expanding their market reach.


Update June 25 2024

As of June 25, 2024, Ginkgo Bioworks (NYSE: DNA) is experiencing a significant decline in its stock performance! An Ai assessment!